10 results
8-K
EX-4.1
RVNC
Revance Therapeutics Inc
14 Feb 20
Entry into a Material Definitive Agreement
5:04pm
Subsidiary not held by such person to the extent required to satisfy local minority interest requirements outside of the United States.
Section 1.02
10-K
2013 FY
RVNC
Revance Therapeutics Inc
28 Mar 14
Annual report
12:00am
on a minority, nonmarketable interest basis. The Company’s aggregate enterprise value was determined using the income approach and a form of market
424B4
pzp3e3
6 Feb 14
Prospectus supplement with pricing info
12:00am
S-1
EX-10.14
rv7tha ltwj
31 Dec 13
IPO registration
12:00am
S-1
gess sfn69z
31 Dec 13
IPO registration
12:00am
DRS
anabxlo6nzdknyzlve
19 Apr 13
Draft registration statement
12:00am
- Prev
- 1
- Next